Cellectis (CLLS) Competitors

Cellectis logo
$1.06 +0.02 (+1.92%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.06 0.00 (0.00%)
As of 05:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CLLS vs. CTMX, TECX, YDES, PRTC, and PBYI

Should you buy Cellectis stock or one of its competitors? Cellectis's main competitors and comparable companies include CytomX Therapeutics (CTMX), Tectonic Therapeutic (TECX), YD Bio (YDES), PureTech Health (PRTC), and Puma Biotechnology (PBYI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellectis compare to CytomX Therapeutics?

Cellectis (NASDAQ:CLLS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Cellectis has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cellectis has a net margin of -396.85% compared to CytomX Therapeutics' net margin of -608.98%. CytomX Therapeutics' return on equity of -33.97% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectis-396.85% -319.93% -46.54%
CytomX Therapeutics -608.98%-33.97%-27.19%

Cellectis currently has a consensus price target of $5.46, suggesting a potential upside of 415.09%. CytomX Therapeutics has a consensus price target of $12.10, suggesting a potential upside of 523.71%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Cellectis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

In the previous week, CytomX Therapeutics had 5 more articles in the media than Cellectis. MarketBeat recorded 9 mentions for CytomX Therapeutics and 4 mentions for Cellectis. CytomX Therapeutics' average media sentiment score of 0.89 beat Cellectis' score of -0.02 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cellectis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CytomX Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

CytomX Therapeutics has lower revenue, but higher earnings than Cellectis. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$79.59M1.34-$67.59M-$1.27N/A
CytomX Therapeutics$76.20M5.55-$17.37M-$0.50N/A

Summary

CytomX Therapeutics beats Cellectis on 11 of the 15 factors compared between the two stocks.

How does Cellectis compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Tectonic Therapeutic has a beta of 3.51, meaning that its stock price is 251% more volatile than the broader market. Comparatively, Cellectis has a beta of 3.21, meaning that its stock price is 221% more volatile than the broader market.

Cellectis has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tectonic TherapeuticN/AN/A-$74.15M-$4.63N/A
Cellectis$79.59M1.34-$67.59M-$1.27N/A

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cellectis had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Cellectis and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.40 beat Cellectis' score of -0.02 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cellectis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tectonic Therapeutic has a net margin of 0.00% compared to Cellectis' net margin of -396.85%. Tectonic Therapeutic's return on equity of -37.69% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Tectonic TherapeuticN/A -37.69% -35.65%
Cellectis -396.85%-319.93%-46.54%

Tectonic Therapeutic currently has a consensus target price of $69.17, suggesting a potential upside of 244.46%. Cellectis has a consensus target price of $5.46, suggesting a potential upside of 415.09%. Given Cellectis' higher possible upside, analysts clearly believe Cellectis is more favorable than Tectonic Therapeutic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tectonic Therapeutic
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.80
Cellectis
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29

Summary

Tectonic Therapeutic beats Cellectis on 9 of the 16 factors compared between the two stocks.

How does Cellectis compare to YD Bio?

Cellectis (NASDAQ:CLLS) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

YD Bio has a net margin of 0.00% compared to Cellectis' net margin of -396.85%. YD Bio's return on equity of 0.00% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectis-396.85% -319.93% -46.54%
YD Bio N/A N/A N/A

63.9% of Cellectis shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cellectis has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market. Comparatively, YD Bio has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market.

Cellectis currently has a consensus price target of $5.46, indicating a potential upside of 415.09%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cellectis is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

YD Bio has lower revenue, but higher earnings than Cellectis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$79.59M1.34-$67.59M-$1.27N/A
YD BioN/AN/AN/AN/AN/A

In the previous week, Cellectis had 1 more articles in the media than YD Bio. MarketBeat recorded 4 mentions for Cellectis and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.62 beat Cellectis' score of -0.02 indicating that YD Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cellectis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
YD Bio
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cellectis beats YD Bio on 9 of the 13 factors compared between the two stocks.

How does Cellectis compare to PureTech Health?

Cellectis (NASDAQ:CLLS) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Cellectis has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Cellectis has higher revenue and earnings than PureTech Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$79.59M1.34-$67.59M-$1.27N/A
PureTech Health$4.66M91.01-$109.74MN/AN/A

Cellectis presently has a consensus target price of $5.46, indicating a potential upside of 415.09%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectis is more favorable than PureTech Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29
PureTech Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cellectis had 4 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Cellectis and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat Cellectis' score of -0.02 indicating that PureTech Health is being referred to more favorably in the news media.

Company Overall Sentiment
Cellectis Neutral
PureTech Health Neutral

PureTech Health has a net margin of 0.00% compared to Cellectis' net margin of -396.85%. PureTech Health's return on equity of 0.00% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectis-396.85% -319.93% -46.54%
PureTech Health N/A N/A N/A

63.9% of Cellectis shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cellectis beats PureTech Health on 10 of the 15 factors compared between the two stocks.

How does Cellectis compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Puma Biotechnology had 3 more articles in the media than Cellectis. MarketBeat recorded 7 mentions for Puma Biotechnology and 4 mentions for Cellectis. Puma Biotechnology's average media sentiment score of 0.50 beat Cellectis' score of -0.02 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Puma Biotechnology
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cellectis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Puma Biotechnology has a net margin of 10.26% compared to Cellectis' net margin of -396.85%. Puma Biotechnology's return on equity of 17.50% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Puma Biotechnology10.26% 17.50% 11.83%
Cellectis -396.85%-319.93%-46.54%

Puma Biotechnology has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$228.40M1.62$31.11M$0.4615.52
Cellectis$79.59M1.34-$67.59M-$1.27N/A

Puma Biotechnology presently has a consensus price target of $6.00, suggesting a potential downside of 15.97%. Cellectis has a consensus price target of $5.46, suggesting a potential upside of 415.09%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Puma Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cellectis
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Puma Biotechnology has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Cellectis has a beta of 3.21, suggesting that its stock price is 221% more volatile than the broader market.

Summary

Puma Biotechnology beats Cellectis on 11 of the 17 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLLS vs. The Competition

MetricCellectisBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$104.35M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-0.8326.7134.3428.32
Price / Sales1.3415.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-5.894.184.453.72
Net Income-$67.59M-$24.15M$3.52B$393.10M
7 Day Performance-23.19%-7.81%-5.93%-5.77%
1 Month Performance1.92%-5.99%-4.58%-7.14%
1 Year Performance-74.21%-8.09%-1.94%-7.46%

Cellectis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLLS
Cellectis
2.6544 of 5 stars
$1.06
+1.9%
$5.46
+415.1%
-74.4%$104.35M$79.59MN/A229
CTMX
CytomX Therapeutics
2.0839 of 5 stars
$1.99
+0.3%
$12.00
+504.5%
-45.4%$432.53M$76.20MN/A69
TECX
Tectonic Therapeutic
2.7087 of 5 stars
$22.10
+1.0%
$69.17
+212.9%
+9.2%$432.13MN/AN/A60
YDES
YD Bio
1.3677 of 5 stars
$6.06
-9.7%
N/AN/A$428.99MN/AN/A14
PRTC
PureTech Health
N/A$17.42
flat
N/AN/A$424.04M$4.66MN/A100

Related Companies and Tools


This page (NASDAQ:CLLS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners